ClinicalTrials.gg
TerminatedNCT03334240Updated Mar 20, 2019

ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

A Phase 2 interventional study of CLS003 and Vehicle in HPV-Induced Genital Lesions, sponsored by Maruho Co., Ltd.. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-20.

Sponsored by Maruho Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of effect in interim analysis

From the registry’s dates

  • Primary completion was Oct 2018, 8 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is intended to explore and evaluate the pharmacodynamics and clinical efficacy of the ionic contra-viral therapy CLS003 in immunocompromised and immunocompetent patients with benign and premalignant HPV-induced genital lesions

Read the detailed description

This study is intended to explore clinical efficacy and safety/tolerability of ICVT as a potential treatment for benign and premalignant HPV-induced genital lesions in immunocompetent and immunosuppressed patients. This includes 3 different patient populations: i) immunocompetent patients with anogenital warts (AGWs), ii) immunocompromised patients with anogenital warts and iii) immunocompromised patients with vulvar high grade squamous intraepithelial neoplasia (HSIL), formerly referred to as usual type vulvar intraepithelial neoplasia (uVIN). Since digoxin / furosemide ICVT's mode of action is in part independent of the immune system and directly targeted to eradicate the causative HPV, we hypothesize this therapy to be of value in this specific group of individuals.

02

Conditions studied

  • HPV-Induced Genital Lesions

Keywords

  • HPV
  • Digoxin
  • Furosemide
  • Vulvar HSIL
03

In context

Lead sponsor

Maruho Co., Ltd. is the lead sponsor of 27 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years in general, stable good health (with the exception of the disorder) as per judgment of the investigator based upon the results of a medical history, physical examination, , chemistry, hematology.
  2. In case of immunocompromised patients including but not limited to; patients receiving immunosuppressive therapy for any reason, patients with auto-immune disease, patients, transplantation patients
  3. In case of genital warts patient group(s): have at least 3 genital warts (only applicable to Study Part 1)
  4. In case of vulvar HSIL: at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥ 20 mm OR in 2 perpendicular dimensions that when multiplied together give a surface area ≥ 120 mm² (only applicable to Study Part 1)
  5. If female of , have a negative urine pregnancy test at Screening and Day 0, and is willing to use effective during the study and 3 months afterwards (i.e. oral, implanted, injectable, IUD, diaphragm, condom, tubal ligation, abstinence, or are in a monogamous relationship with a partner who has had a vasectomy)
  6. Able to participate and willing to give written and to comply with the study restrictions
  7. Ability to communicate well with the investigator in the Dutch language
  8. Willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Significant, uncontrolled or unstable disease in any organ system as per judgment of the investigator (regardless of association with the disorder/therapy), including but not limited to: psychiatric, neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, hematologic or respiratory disease
  2. Have used or received any topical genital wart treatment, cryotherapy, electrocoagulation, surgery in the treatment area within 28 days prior to enrolment
  3. Have used or received any topical vulvar HSIL treatment, laser therapy or surgery in the treatment area within 28 days prior to enrolment
  4. Have any current relevant skin infections in the treatment area other than genital warts (inclusively, but not limited to atopic dermatitis, lichen sclerosis, lichen planus or psoriasis)
  5. Have a known sensitivity to any of the product ingredients, including digoxin and furosemide
  6. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year
  7. Loss or donation of blood over 500 mL within three months prior to screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    CLS003

    Digoxin and Furosemide topical formulation

    Drug: CLS003

  • Placebo comparator
    Vehicle

    Inactive vehicle

    Drug: Vehicle

Interventions

  • DrugCLS003

    CLS003

  • DrugVehicle

    Vehicle

06

What researchers measure

Primary outcomes

  1. Lesion (vulvar HSIL or wart) size reduction

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  2. Change in patient-reported outcomes

    Time frame: Through study completion, up to 20 weeks

  3. HPV viral load assessment

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  4. Change in the HPV viral load

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  5. Mean HPV viral load

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  6. Histology (regression of vulvar HSIL or AGWs to no dysplasia, HPV genotyping)

    Time frame: Day 0, 42, 126, (Part 1 of study), Day 56 (Part 2 of study)

  7. Local immunity status

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  8. Percentage clearance of vulvar HSIL lesions

    For vulvar HSIL cohort

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  9. Proportion of patients with all vulvar HSIL lesions cleared

    For vulvar HSIL cohort

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  10. Histology (regression of vulvar HSIL to no dysplasia)

    For vulvar HSIL cohort

    Time frame: Day 0, 42, 126, (Part 1 of study), Day 56 (Part 2 of study)

  11. Histological recurrence in the Part 1 follow-up period

    For vulvar HSIL cohort

    Time frame: Day 84, 126

  12. Percentage clearance of genital warts

    For genital wart cohort

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  13. Proportion of patients with all genital warts cleared

    For genital wart cohort

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)

  14. Clinical recurrence in the Part 1 follow-up period

    For genital wart cohort

    Time frame: Day 84, 126

Secondary outcomes

  1. Adverse event collection to assess safety/tolerability of CLS003

    Time frame: Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study), and as volunteered by patient

07

Study locations

1 site
  • LUMC/Centre For Human Drug Research
    Leiden, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Oct 2018, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 7, 2017
StartActual
Oct 5, 2017
Primary completionActual
Oct 30, 2018
CompletionActual
Oct 30, 2018
Last update
Mar 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03334240
Lead sponsor
Maruho Co., Ltd.
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Oct 5, 2017
Primary completion
Oct 30, 2018
Completion
Oct 30, 2018
Last update
Mar 20, 2019

Study contacts

J. (Koos) Burggraaf, MD, PhD
principal investigator · Centre For Human Drug Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide/Digoxin Topical Gel CLS003

Start the discussion